Sepsis Diagnostics Market to Reach US$ 1.63 Billion by 2032, Driven by Advances in R&D and ICU Admissions

Increased prevalence of pediatric and neonatal sepsis, coupled with advancements in automated diagnostic technologies, are key growth drivers.

The updated sepsis diagnostics market analysis from Fact.MR anticipates a robust development trajectory for FY 2021-22 and beyond, with the market predicted to expand at a CAGR of over 8% through 2032. Prospects for growth were further bolstered by the coronavirus pandemic, which was connected to the advent of pneumonia-induced sepsis and subsequent mortality.

According to the analysis, the market is predicted to generate over US$ 1,630 Million in revenue by 2032, resulting in strong short-term benefits. These are mostly related to current R&D projects, as well as an increase in ICU and hospital admission-induced sepsis among patients. Manufacturers are adopting cutting-edge automated technology to provide accurate and rapid diagnosis.

Epidemiologically, an estimated 22 occurrences of paediatric sepsis and 2,202 instances of neonatal sepsis per 100,000 live births occur. This equates to 1.2 million instances of paediatric sepsis per year. According to the most recent estimates, an adult prevalence rate of 19.4 million sepsis episodes, with over 5 million fatalities, exists. As a result, efforts are being made to develop more complex sepsis diagnostic techniques, which are projected to increase demand in the future years.

For More Insights into the Market, Request a Sample of thisReport: https://www.factmr.com/connectus/sample?flag=S&rep_id=391

Key Takeaways from the Market Study:

1. Global sepsis diagnostics market to more than double in value terms by 2032
2. By product, demand for assays and reagents to reach US$ 300 Million in worth by 2032
3. U.S to be an opportunistic market, expected to flourish at a 7.8% value CAGR
4. Germany and India to register CAGRs worth 7% and 6.6% respectively
5. China to yield a market value of US$ 750 Million by the end of the forecast period
6. By 2022, global sepsis diagnostics market demand to reach US$ 755 Million.

“As the frequency of hospital admissions for various diseases increases, risk of developing sepsis during treatment is rising, prompting healthcare settings to incorporate sepsis diagnostics and detection systems, spurring heightened R&D to introduce new solutions,” comments a Fact.MR analyst.

Competitive Landscape

The existence of a large number of diagnostic service providers peppers the global sepsis diagnostics market, making it extremely competitive. Among all of the expansion techniques used, providing technologically superior solutions through extensive R&D remains the primary goal.

• For example, Luminex Corporation, a diagnostics testing pioneer, provides the VERIGENE® and VERIGENE® II Systems, which are especially intended to target infections in the bloodstream, respiratory tract, and gastrointestinal tract. These technologies employ highly automated processes to aid in extraction, amplification, hybridization, and detection, therefore improving clinical outcomes by avoiding the start of sepsis.
• Similarly, Abionic SA provides the abioSCOPE, a non-fluidic immunoassay technique that was tested on hundreds of patients across 14 European hospitals, with doctors verifying that in more than 85 percent of instances, sepsis identification was achievable more than 24 hours prior to conventional care. In 2020, the solution was approved for clinical testing in hospitals across the United States.

Leading Players Driving Innovation in the Sepsis Diagnostics Market:

Key industry participants like BioMerieux SA; Becton Dickinson and Company (BD); Thermo Fisher Scientific Inc.; Abbott Laboratories Inc.; Roche Holdings AG etc. are driving the sepsis diagnostics industry.

Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=S&rep_id=391

More Insights Available

Fact.MR, in its new offering, presents an unbiased analysis of the global sepsis diagnostics market, presenting historical analysis from 2015 to 2021 and forecast statistics for the period of 2022-2032.

The study reveals essential insights on the basis ofproduct (blood culture media, instruments and assays & reagents), method (conventional sepsis diagnostics, automated sepsis diagnostics, pathogen, gram-negative bacterial sepsis, gram-positive bacterial sepsis, fungal sepsis and other pathogens), and technology (microbiology, molecular diagnostics, immunoassays and other technologies) across six major regions (North America, Latin America, Europe, APEJ, Japan and Middle East & Africa).

Check out More Related Studies Published by Fact.MR Research:

Rapid medical diagnostic kits market size is anticipated to reach a value of US$ 17.6 billion in 2024. Worldwide revenue from the sales of rapid medical diagnostic kits is projected to increase at a CAGR of 4% to reach US$ 26 billion by the end of 2034.

Infectious disease diagnostic market size is valued at US$ 1,503.8 million in 2024, and it is estimated to expand at a 7.1% CAGR, reaching a valuation of US$ 2,978.7 million by 2034.

Critical care diagnostics market analysis reveals that the global market reached a valuation of US$ 1.1 billion in 2020, and is anticipated to top US$ 1.7 billion by 2031, expanding at a CAGR of 5.5%.

Home diagnostics market is valued at US$ 6.21 billion in 2023 and is forecasted to expand at a healthy 5.2% CAGR over the next ten years. Worldwide home diagnostics demand is estimated to reach a market size of US$ 10.32 billion by 2033-end.

Viral disease diagnosis market is analyzed to reach US$ 55 billion in 2024 and is forecasted to expand at a CAGR of 9.8% to achieve a valuation of US$ 139.93 billion by 2034.